Evidence map›Paper›PMID 41390473›Full record

ReviewCell death discovery2025

Glutamine: fructose-6-phosphate amidotransferase (GFAT) in the pathology of diseases: a review.

Caiting Yang, Fengyu Chu, Xiaoli Chen, Fanqi Meng, Yinhao Li, Jingwen Chen, Chaoyang Sun, Yahui Shang, Ruibin Guo, Jianming Wang and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Caiting Yang *Shanxi Provincial Key Laboratory for Medical Molecular Cell Biology, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education and Institute of Biomedical Sciences, Shanxi University, Taiyuan, Shanxi, China.
Fengyu Chu *Shanxi Provincial Key Laboratory for Medical Molecular Cell Biology, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education and Institute of Biomedical Sciences, Shanxi University, Taiyuan, Shanxi, China.ORCID http://orcid.org/0009-0000-7582-8556
Xiaoli Chen *Shanxi Provincial Key Laboratory for Medical Molecular Cell Biology, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education and Institute of Biomedical Sciences, Shanxi University, Taiyuan, Shanxi, China.
Fanqi MengShanxi Provincial Key Laboratory for Medical Molecular Cell Biology, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education and Institute of Biomedical Sciences, Shanxi University, Taiyuan, Shanxi, China.
Yinhao LiShanxi Provincial Key Laboratory for Medical Molecular Cell Biology, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education and Institute of Biomedical Sciences, Shanxi University, Taiyuan, Shanxi, China.
Jingwen ChenShanxi Provincial Key Laboratory for Medical Molecular Cell Biology, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education and Institute of Biomedical Sciences, Shanxi University, Taiyuan, Shanxi, China.
Chaoyang SunShanxi Provincial Key Laboratory for Medical Molecular Cell Biology, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education and Institute of Biomedical Sciences, Shanxi University, Taiyuan, Shanxi, China.
Yahui ShangShanxi Provincial Key Laboratory for Medical Molecular Cell Biology, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education and Institute of Biomedical Sciences, Shanxi University, Taiyuan, Shanxi, China.
Ruibin GuoDepartment of Oncology, General Hospital of Yangquan Coal Industry Group; Department of Oncology and Interventional Radiology, Yang Quan Hospital of Shanxi Medical University, Yangquan, Shanxi, China.
Jianming WangDepartment of Oncology, General Hospital of Yangquan Coal Industry Group; Department of Oncology and Interventional Radiology, Yang Quan Hospital of Shanxi Medical University, Yangquan, Shanxi, China.
Changxin WuShanxi Provincial Key Laboratory for Medical Molecular Cell Biology, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education and Institute of Biomedical Sciences, Shanxi University, Taiyuan, Shanxi, China.
Huiping DuanTuberculosis Department, Fourth People's Hospital of Taiyuan, Taiyuan, Shanxi, China. duanhuiping461@163.com.ORCID http://orcid.org/0009-0000-3916-4182
Miaomiao ShaoSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. shmm16@njucm.edu.cn.ORCID http://orcid.org/0000-0002-4847-2424
Wei YuanDepartment of Oncology, General Hospital of Yangquan Coal Industry Group; Department of Oncology and Interventional Radiology, Yang Quan Hospital of Shanxi Medical University, Yangquan, Shanxi, China. lvyingyw@126.com.ORCID http://orcid.org/0000-0003-2322-9820

Funding

Natural Science Foundation of Shanxi Province (Shanxi Province Natural Science Foundation) 202403021221004, 2024030212211348, 202203021221300
6 · The paper itself

Abstract

Glutamine: fructose-6-phosphate amidotransferase (GFAT), a conserved enzyme across prokaryotic and eukaryotic species, is the first and rate-limiting step in the hexosamine biosynthetic pathway (HBP), diverting 2-5% of fructose-6-phosphate derived from glucose toward the synthesis of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), a key substrate for the glycosylation of proteins and lipids. While substantial progress has been made in elucidating the basic biochemical properties and regulatory mechanisms of GFAT, its functional impact on pathological processes remains incompletely understood. Emerging evidence implicates GFAT in a spectrum of human diseases, including cancer, diabetes, cardiovascular disorders, and neurodegenerative conditions such as Alzheimer's disease. This review aims to provide a comprehensive synthesis of current insights into GFAT's role in disease etiology, with the goal of informing future research and therapeutic strategies targeting this essential metabolic regulator.

Identifiers

PMID41390473
PMCPMC12847842

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.